Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07646301 | Jul 2026 → Dec 2028 expected | uterine cervix neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646301 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab (QL1706)” NCT07646301 ↗ |
| Modality | Monoclonal antibody | “a dual PD1and CTLA4 bispecific antibody” NCT07646301 ↗ |
| Route | Intravenous | “250 mg administered intravenously over at least 30 minutes” NCT07646301 ↗ |